Cencora, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Robert Mauch
- Full Time Employees
- 49,000
- Sector
- Healthcare
- Industry
- Medical - Distribution
- Address
- 1 West First Avenue Conshohocken PA United States of America 19428-1800
- IPO Date
- Apr 4, 1995
- CIK
- 0001140859
- Website
- cencora.com
- Similar Companies
- Business
- Cencora, Inc. (NYSE: COR) serves as a leading global pharmaceutical solutions organization that provides end-to-end pharmaceutical distribution, commercialization support, and related services to manufacturers, healthcare providers, pharmacies, hospitals, and health systems worldwide. Founded in 1871 and headquartered in Conshohocken, Pennsylvania, the company operates through U.S. Healthcare Solutions and International Healthcare Solutions segments; it distributes brand-name, specialty brand-name, generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment; offers wholesale and specialty distribution, pharmacy solutions, provider solutions, hospital and health system solutions, logistics and warehousing, drug research and clinical development support, commercialization support, and patient access and adherence programs; and serves acute care hospitals, independent and chain retail pharmacies, mail-order facilities, physicians, clinics, long-term care, assisted living centers, workers' compensation patients, and alternate site facilities across the United States, Canada, and other international markets. In recent developments, Cencora changed its name from AmerisourceBergen Corporation in August 2023; entered a definitive agreement in November 2024 to acquire Retina Consultants of America, a management services organization for retina specialists, for approximately $4.6 billion in cash plus up to $500 million in contingent consideration to expand its specialty capabilities and physician relationships; and announced in November 2025 a $1 billion investment through 2030 to strengthen its U.S. distribution network, including a new 530,000-square-foot national distribution center in Harrison, Ohio by spring 2027, expansions in Fontana, California and Dothan, Alabama with advanced automation and increased refrigerated capacity, and enhanced global cold chain logistics with a new third-party logistics facility planned in Italy in 2026.
Company News
Here's Why Cencora (COR) is a Strong Momentum Stock
Cencora, Inc. (COR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Why Cencora (COR) is a Top Growth Stock for the Long-Term
Here's Why You Should Retain Cencora Stock in Your Portfolio for Now
Cencora (COR) Up 3.8% Since Last Earnings Report: Can It Continue?
Cencora Launches Cell and Gene Therapy Enablement for Health Systems
Cencora Raises 2026 EPS Outlook as Specialty Businesses Strengthen
Cencora's Accelerate Pharmacy Solutions Launches Cell and Gene Therapy Enablement to Help Health Systems Build and Scale Programs
Connor Clark & Lunn Investment Management Ltd. Invests $841,000 in Cencora, Inc. $COR
Invesco Discovery Mid Cap Growth Fund Q2 2026 Portfolio Performance
Advisors Capital Management LLC Takes $748,000 Position in Cencora, Inc. $COR
"Trumpflation" Is Real -- and Getting Worse. Here Are 2 Stocks That Turn Rising Prices Into Rising Profits.
Why Cencora (COR) is a Top Value Stock for the Long-Term
Cencora, Inc. (NYSE:COR) Given Average Rating of “Moderate Buy” by Brokerages
Why Cencora (COR) is a Top Momentum Stock for the Long-Term
Here's Why Cencora (COR) is a Strong Growth Stock
Allspring Growth Fund Q2 2026 Performance Update
Cencora Q3 Earnings Call Highlights
Cencora, Inc. (COR) Q3 2026 Earnings Call Transcript
Cencora Sees Specialty Growth Continue While GLP-1 Mix Weighs on Margins